Deciphera Pharmaceuticals (DCPH) 4 Aug 212021 Q2 Earnings call transcript

Good afternoon, everyone, and welcome to the Deciphera Pharmaceuticals Second Quarter 2021 Financial Results Conference Call. Today’s call is being recorded. At this time, I would like to turn the call over to Jen Robinson, Vice President of Investor Relations, Jen?

Thank you operator. Welcome, and thank you for joining us today to discuss Deciphera second quarter 2021 financial results. Vice Relations Robinson, Deciphera. Jen am President, at Investor I Executive financial to provide Steve With and Chief Tucker Chief Medical afternoon Financial Sherman, the Officer; Hoerter, Dan results Matt Commercial and Kelly, are me this Officer; update discuss and Chief Martin, corporate a President Officer. Chief Officer; general

of I are to on expectations remind begin, that are made forward-looking call beliefs this reflecting management, not that current any we the Before facts to you forward-looking Safe preclinical Litigation Harbor include Provisions would Reform our like historical guidance. Act of statements the our make made QINLOCK the statements pursuant clinical and we Private of Securities XXXX. during of Examples statements for XXXX commercialization call conference this programs, our expectations and of and

on risks we call Such on that Form achieved. expectations you forward-looking report set SEC our from those will risks revise well as and update made actual obligation to our the as statements by cannot filings. or quarterly and other in and implied substantial to those this forward-looking differ be uncertainties results any involve statements, assure assume recent XX-Q no expressed most materially cause could our Forward-looking uncertainties statements. include that We forth or

Deciphera. made Following Steve to Hoerter, www.deciphera.com. be call, will this a company’s the replay Executive call over President of available website, now Officer the on Steve? will With Chief turn that, I and

Jen. you, Thank

set half for across of a company’s half first the the we catalyst-rich to for the will growth. phase priorities of the year During XXXX, us strategic stage that next the continue positioning on execute of company, our second

created QINLOCK commercial rapidly Dan today’s a outline the Officer, strong on our of expansion has for fourth-line call, into will second-line established our standard organization U.S. future As the in which setting. care our foundation GIST, Chief Commercial has as Martin,

launches provides the best-in-class clinical addition, publish QINLOCK benefit studies, Hong we underscore from medicine and key are in China of making States, underway the to updates United GIST. progress which in broad we In now with continue Kong. Outside this data excellent

in an Lab, diagnosed China As this territory. estimated launch marketing This once an experienced Zai we each the supporting partner, as reminder, our deliver a In approval the well new GIST Europe, building European patients quickly in for we the fourth look that they markets review, application Agency will with forward to year, our patients be the organization important authorization preparing approval in QINLOCK year. launch is where in XX,XXX is to and are by is EMA are out focused commercial positioned Medicines early quarter of expected secured. team to QINLOCK this under

medicine next priority for earlier lines of moving into QINLOCK Our GIST. is for therapy this

the fourth-line make has patients earlier the We in have QINLOCK to GIST able that significant lines seen eager of are been treatment. patients with impact to to in of bring and difference lives life-changing

in this to We Phase of announce ongoing INTRIGUE line the from fourth study results continue to quarter in GIST, second-line year. top expect the X

with kinase novel of our is QINLOCK, the we on study investigating safety patient tolerability June, This focused In first-in-class advancing pipeline Inhibitors. DCC-XXXX. growing treated Kinase study and in X first monotherapy the our addition of to Phase remain first X help potential of very have of In our that we RAS as regulators in of tumors ULK Phase inhibitor, to in the a believe a holds RAF then with position MEK or gene for patients cancer, leading a and we group inhibitor. of a patients. mutant tremendous large expressing combination an solid We autophagy in approach development

autophagy and VPSXX, pleased in regulating science Sprint more targeting stage expertise research on in autophagy Bioscience another agreement to Officer, program research builds the for detail, we DCC-XXXX complementary an and Chief their the our for today Medical with to in exclusive a cancer. Sherman, This is As announce discuss were pathway. important program Matt kinase will licensing

now ESMO pleased presenting programs. Vimseltinib data with Rebastinib X/X results also to look with programs upcoming development half cohort are Dan? Phase the pivotal call to forward the in Chief to patients we Dan our Officer, in over cell Martin, we the the I the second our data ovarian We turn Phase Congress, new tenosynovial paclitaxel. progress in Commercial studies commercial development Xb/X from discuss from later-stage from U.S. platinum-resistant from of are the QINLOCK making for year. to in plan giant tumor, study the finalize addition both At combination to cancer QX. will with of the of We the with clinical

market the team In launch May opportunity. care commercial established our initial the in to in our Since year, you, Steve. penetrated fourth-line we the objectives. last continued core and have have as of against execute rapidly indication QX, our Thank clear of QINLOCK standard fourth-line approval

clinical product Importantly, key share net million the high QX, pandemic, physician QX, QINLOCK more setting. than Since experience extremely awareness among both among achieve $XX lingering GIST million challenges footprint. total product both academic prescriber QINLOCK’s performance in to to QINLOCK. remain familiarity positive of prescribers in launch GIST XXX our continued product revenue prescribers positive across high. our to and targeted broad our expand achieved over physicians advance the metrics remain larger cite significantly the we QINLOCK the settings and representing capitalize In clinical launch, community treaters as fourth-line community provide for reach to we by $XX.X XXX globally, and continue opportunity levels opportunity. benefit perceptions we second-line sales created And and marketing U.S. prescribed institutions teams have of on to performance we from strong voice. extremely QINLOCK prescriber and attributes. Despite built in significant In continue including also of the in planned have of academic into access continued all

our coming from prescriber now is setting. up while community our academic the physicians earliest of expected, new most As the growth majority of made adopters,

with relates larger second-line it expect but to pleased it progress play current differentiated community role QINLOCK’s to Overall, as to as planned reflects of we practices, are not our in profile and treat fourth-line even We success and also proven community difficult academic an within clinical disease. our highly we believe community to benefit our is settings across as only our relates date prescribers therapy. launch, launch to lines earlier historically both patient and

we duration what to our we the consistent patients study, that see have pre-launch who the similar in expectations. continues received real-world with to of be INVICTUS Regarding for QINLOCK therapy, persistency saw

on shared longer on for be which we from have we remained therapy average than therapy on median, our based eventually the previously, As expect periods. to trials, experience in clinical time patients extended the some

COVID visits having into estimates continue IQVIA Recent in pandemic to oncology of has through on has data year. just oncology IQVIA first XXXX. that show impact XX% specifically. the impact monitor and now the the that broadly persisted total We negative the diagnosis the from impacted by negatively is that half this pandemic’s prescriptions

Regarding continue lines to an volume, approximate GIST claims year. of earlier patient the patient XX% show past data new over decline starts therapy in in

is that pre-pandemic particularly COVID for of impact given a the lack comparison. we Assessing challenging, baseline

fourth on these suggest that having the together, line to COVID data treatment. patients impact progressing taken volume an be of GIST However, may

FDA patient see with during excellent policies core our the objectives and payer One to QINLOCK, optimize quarter to pleased is of coverage to aligned label. we to very continued our access were

patients percentage under an receiving versus the program increased quarters. Regarding our drug PAP, trend or QX of we assistance free patient in saw prior

trend higher XX%. the estimated within For program This of result calendar D mind drug through of year. PAP percentage end drug program appears was the range. important patient to QX must by and keep QX, patient is although that levels Part increased in potentially PAP from our challenging, the persist Medicare that remain our in we under future the quarter, who that Therefore, XX% the benefit end range affordability PAT receive It’s company’s to exceeding at to patients to free expect quarters estimated design. driven high be projecting assistance the in a Medicare of see challenges

approval. line ahead, launch, preparations pending we FDA As our for planned are underway second look

We potential the a about setting, by patient anticipated population the second-line and for significant are larger estimated longer therapy. of extremely optimistic QINLOCKin driven duration

expanding desire GIST, over our QINLOCK of potential the more to and use on need To consistently seen indication have in for We option. by patients in a that In for their look we just impact shared had market programs. turn foundation in progress believe to data recognized positive of future. I and pending success underscoring impact population setting, pending FDA and patients discuss strong the treatment QINLOCK approval. community second-line date, Matt leaders QINLOCKs just research, to on later is provides the improved year profound regarding the even to oncologists the and Matt? a helping we now second-line fourth-line patients have GIST an INTRIGUE the call will widely forward clinical to our approval. second-line, of to treaters, positively shared by enthusiasm a this building broader into Our GIST QINLOCK from subsequent the has the of thought treatment foundation with initial

Thank you, Dan.

inhibitors. DCC-XXXX expanding cancer quarter treatments. patient The cancer an autophagy, the to to kinase DCC-XXXX by cancers. energy. treatment and utilize sales focus ULK on of first-in-class generate RAS by often growth progress which believe achieved inhibiting be important which upregulated in DCC-XXXX, in start will the I’d we This autophagy discussing of by newest kinase, inhibitor RAS to due is top an the a for factor was today mutant, caused first-in-human ULK to exciting marked dosing study. documented inhibit development like tumor components in the topic our we and RAF and is designed novel initiating Phase program, which development to first damage Autophagy survival. stressed clinical the X impressive RAF clinical for recycle DCC-XXXX pathway. plan a to designed the our anticancer kinase June, process suppress in in key In milestone by mutations, the pipeline important is cells

MEK in results planned tumor commercially types. in combination cohorts expansion positive dose-escalation multiple the are Assuming currently trametinib, in a phase, with available inhibitor

kinase to other explore in are combination expect pre-clinically, that. RAS We to beyond map for evaluate other it we partners pathway signaling DCC-XXXX and with with inhibitors the continuing combination

demonstrating potentially generated meeting. has look We oncology an forward DCC-XXXX preclinical multiple team in sharing at broad targeting applicability ULK upcoming combination tumor autophagy important in data types, medical research Our addition. approved in some with targeted of to exciting work to agents with additional

as does Our an autophagy the pathway of enthusiasm oncology in for with DCC-XXXX. important end potential targetable not

in a As Steve the explore to stage growing the targeting complements mentioned, XX. rights pipeline The programs exclusive autophagy cancer ULK regulating approach research the our number benefit our robust comprehensive for VPS-XX program efforts Together, large in-licensed and program to in antophagen potential research a cancer. to addressing with represent very internal to enhances patients. of potential of we VPS and programs clinical the a Deciphera’s VPS-XX role

present to we clinical on this annual and were the Moving meeting. programs, other kinase to data QINLOCK, both year’s from excited ASCO studies our at

an QINLOCK were published XXX For that can presented Phase additional the in QINLOCK, X peer tolerable review last study milligrams exploratory substantial milligrams oncologist journal on BID of dose the with we the of safety offer XXX week. profile. our QD, showing of a clinical progression analysis data escalation benefit just INVICTUS after These

data pleased meaningful QINLOCK’s of in potential patients with the As offer continues disease. are safety GIST supporting of settings grow, efficacy clinically for to the body and we multiple to benefits this

chemo to support excited plus we of GIST. GIST patients INTRIGUE. year Plan remain significant inhibitor as expected will post-imatinib initiate Phase PFS results combination quarter, the for in data patients ongoing sunitinib mechanisms the we of that these to of fourth-line data X Phase as clinical a showing potential GIST, the that fourth patients. a X top-line Phase study study median available second-line the success Phase Xb/X of the X.X with the resistant commercially quarter for the of months the comparing likelihood INTRIGUE benefit the QINLOCK receiving in We For demonstrate fourth believe one well this in with MEK exceptional to strongly INVICTUS optimistic binimetinib, with are in X address the QINLOCK

QINLOCK goal before, to patients kinase deepen new with this stated and the prolonged MEK the of of is we fostamatinib responses with whether GIST. inhibitor addition with using initial by an a MEK we As pathway for see addition combining can study broad

in X have We in utilizing been combination inhibitor carboplatin. Simon Phase, TIEX in selective and studying a design paclitaxel study Xb/X also X-stage our with Rebastinib, with combination

data the study, ESMO combination the For phase at have dose-escalation three been year tumor-specific carboplatin we last presented from evaluating and expansion preliminary cohorts. of the

have carboplatinum and paclitaxel safety seen clinical expansion not resources our profile, activity have in activity is focus the time necessary we continue for we we and development additional to this While have decided a seen in that tolerable the to combination. clinical level of believe Rebastinib

look half for population. in activity year. clinical literature this presenting Based results next the which look We month. continue plans plan full approximately at stage, Rebastinib and informative survival, in cancer indicator ovarian updated to ESMO the to September. We second is the study, combination in cancer of paclitaxel forward data the single-agent to data difficult-to-treat these platinum-resistant patients this finalize updated progression-free expected we months. of in in on We ESMO paclitaxel the to cohort updated X with ovarian safety Congress to the sharing platinum-resistant forward efficacy patient on is include and we typotaxin believe including published the key development The of generate the in cohort in to data second from will X data be pivotal at

Finally, the ESMO our believe Vimseltinib pivotal this ESMO, over financial CSFXR of of turn patients. continued in the inhibitor to expect in updated of study look to present which to guidance Telly, plans updated September, excited tenosynovial and progress I Congress with needs. Tucker lives data efficacy at which be are each treatment the safety along development call we X/X to tumor the fulfill Financial XX the the for to of make medical difference we from for these At in will now patients program. potential the Officer, ongoing data share results. our this to We for a giant year’s and on the best-in-class cell Phase to unmet meaningful review TGCT Chief approximately current programs, of Tucker? has forward we

$XXX,XXX the in QINLOCK XXXX with and agreement and royalty the second annualized of of for Total $X.X quarter of our expect in I’d quarter we to Matt. QINLOCK U.S. include to in June second cost the be Thanks, Zai it product sales gross sales financial collaboration XX, Greater product product $X.X revenue the which supply Net million, for $X.X of cost quarter significantly results. for Lab net ex product revenue was China. quarters. for which The cost and line revenue second highlights QINLOCK. of sales in X of million, to estimate from estimate million more under our XXXX, revenue quarter net of was second of of sales the includes $XX.X commercial was $XX.X months XX% million. below like included The which ended in revenue U.S. million, XX% adjustment in our million for QINLOCK with net with view quarter Collaboration the and was our in $XX $XXX,XXX future revenues includes efforts.

quarter to As Total the were inventory expenses in the in expenses through initial additional and of to in million of pre-launch expect the development sales Research XXXX depleted is we same $XX.X general sales expenses we $XX were were immaterial the and $XX.X inventory compared of million cost $XX.X would significant be cost in in in product $XX.X not second $XX of operating compared the have million said second expect, is same second Selling, the compared administrative period remain manufactured previously, in in will net and same period the to million to and at quarter sold. XXXX. operating total the XXXX. period this expenses year the million million in and XXXX. quarter U.S. least the in until

first XXXX. cash, the strong now securities cash financial be pipeline, invest Europe. expect and into increase executing to year and $XXX call QINLOCK U.S. that ended we of development as the which position expect the second commercialization a our operating operations fund in and will the potential in half expenses remain to back I in with launch of of over to this quarter the prepare continue we turn million, well of in our commercial will modestly our capitalized Steve. that, for clinical marketable to sufficient With We equivalents the We approximately

you, Thank Tucker.

We make across strategic continue important XXXX. to priorities in progress our

While are this QINLOCK QINLOCK results in top the care QX study results INTRIGUE the filings the with our world, world on the to for line as enable the around to standard GIST. year. patients been excited If we report dramatically benefit establishing of focus has the around we as of from potential in GIST prepare successful, study these fourth-line will expand and

in quarter QINLOCK. recent progress the most pipeline our has Our strength demonstrated this of beyond

plans and finalizing sharing Rebastinib now year. X later and I’d We successfully call data study for pivotal Vimseltinib Phase forward Operator, open to look like we development to the the Q&A. of DCC-XXXX and this new have initiated for

first [Operator from you. thank our JPMorgan. from Fye And question And Instructions] comes Jessica

is now line open. Your

insight Fye. Hi, Jessica whether first COVID of Thanks you for into new last drug starts first therapy an on In your any impact and for does question. evolved Do remarks, well duration year question. described has this second of kind how prepared Daniel the the you half free and taking is our that COVID on make on over as of That’s XXXX? have have – you of use. as new my patient impact

Second had we seems previously smaller line is than the addressable anticipated. question market fourth

us as we in in patient of number Phase that platinum-resistant scans? ovarian wise for what gives see line you INTRIGUE data true about can we the the is, for the same the question second not opportunity, last And Xb/X terms readout the stage Thanks. approach As think confidence number Rebastinib cancer and line opportunity? as second of the can well settings what be set will study that you maybe of

all Great, Steve. It’s Daniel. questions. the Thanks for

do ask the up in relates these the cancer the second ask to a platinum-resistant to talk COVID at some you take cohort color then about. which ovarian can and I’ll Maybe next what little about try performance I’ll coming in impact order. question, fourth your take to question, we’re will first we bit is and excited line will add to additional take then somewhat I extent, here So Dan the as the that’s data well, and Matt the month which

reiterating the respect in remarks, that your said start really Dan just I prepared with think due sets out, first, how quarter INTRUIGUE the which to I’ll on fourth-line pointed I question in we performance as are by out read to U.S. said which the pleased is is date four. launch with study, and the the the second in you this and So, to line opportunity, stage, what for

So flow the we largely new established really the sets care the a the Dan with to remarks, in outlined community the drug as for think that then of fourth-line coming and prescribers as large would with that. standard of now INTRIGUE into docs indication with year having readout prepared now, us filings in his this – fraction from the the later second-line from of community this study move stage with

respect I as line of the this drivers fourth to demand the the underlying remain the indication about same fourth dynamics in we on think demand the talked line that see with one we in call. quarter

that coming the treatment. X,XXX patients patients. And in number going we is know, the in two to the being in driven in to the driver the So in second-line, that’s line at And see One we by U.S. the second we growth, number just believe, on about to related that we from of you be duration noted second-line of eligible second indication. the estimate leg going was treatment second that factors. next And big patients call line. we larger the as up of the thought really be is of

readout. about ovarian two the as pending then, cohort to you to as opportunity, second reminder, like the think question Matt, And cancer take would question? to are look INTRIGUE Dan, for factors a those line platinum-resistant COVID the the So, just really we the ESMO.

Daniel. absolutely. the Yes, question, Thanks for

patient specifically. just and note we at it’s therapy to starts that to year some the you that having make try COVID over impact in assess of lines to mentioned, just Pat. I And look approximately impact think to we that the I And the data what potential points did impact just So earlier to of broadly is to clarify, track sure continue I’m we clarifying asked of on XX%. and new about what oncology last of

to of for and as QX high of of COVID-impact Pat enter We patients way haven’t who And balance of duration? in have we any program end that increased the able on that into provided, not. but that path may have because estimated to the potentially COVID about our program we works, the COVID we’ve And to specifically lastly, we higher QX in is spoken that calendar no, we then the Pat. levels expect I was discern above of talked remain the the short where on year, into path QX, range. range at didn’t to the impact are persist tie specifically. answer that And

be really received to seeing pleased from launch. continue We who with off that the in we’re persistency came patients

INVICTUS developed we noted, we it’s in As saw study. like and we lot the a as expected looks what

hi, Matt. this And Daniel, is

Let pickup the update ESMO ovarian we question in Rebastinib data the that cancer next to meeting. platinum-resistant at about plan month’s me

meeting part for at X As that ESMO you year cancer expansion we the year a design the was presented first the platinum-resistant and ago. the of remember, ovarian Simon cohort two-stage it ago XX a response response of rate of XX in the time, had XX%. that patients or evaluable we And reported was at that having and X study. the And we early protective a

we for And in we have and only on the now provide survival an evaluable response XX be but enrollment in the completed will also able So objective progression-free we not expansion the to this cohort of update now rate, patients. cohort have patients.

to So, we look next data forward month. that providing

very you much. Thank

Chris comes question next Sandler. Raymond Piper And from you. thank from our And

is open. Your line now

some explore already mentioned line. there the last think I you line question. it wanted the starts think what was And last Dan I I I was therapy. I I that heard just in thanks. think But growth. my goes, from quarter had it to you growth, on U.S. Dan, quarter-on-quarter patient heard revenue GIST lines I maybe were of penetrated, Hey, well to fourth looks say no X% like as earlier inferred think math which

So just talk escalation what’s there the also ASCO. we dose question did Last a a you that? sort about heard check, are use data clarify, at that you of see maybe data some time which if driving it’s anecdotal penetration seeing can growth really Maybe there is to you Can provide? Just the driving pre-ASCO is data Is on employment on indication any the second if net was is can gross sort didn’t out not fourth just benefit? we you and line? about then could Thanks. intra-patient of I think maybe what’s you growth, other that guys color of increased you docs – in the break or I any how that. docs? doing talk of resonating any broadly that with the And

Chris’ It’s Chris. both take of like questions for you Steve. question. the there? Thanks to would Dan, Hey,

appreciate the Absolutely. I Thanks, sure. Chris. question. Yes,

then when So, we and about the respect sort of the think and we story the the And terms that demand about how quarter, in for impact to with story the quarter-over-quarter, it of performance try to think PAP to we gross of that’s and out things net. quarter. X% this

the limited opportunity. all because And we previously benefit now particularly drug we’ve PAP is That design that QINLOCK this to saw, exited that which Part we our quarter a and unchanged, things component of of in to demand, be and and data to program, And opportunity that’s program that Medicare a We then as spoke in we consistent that the QX to that higher planned attribute are it we’ve until in suggest patients growth net, As gross benefit that lower you as noted, That’s QX what increase our that’s we percentage, in the an communicated expect the for demand to PAP to sources expecting said, potentially share, as Tucker fourth-line why did bit to they higher program. the D second-line continue relates that is And from as importantly, how well. quarter-over-quarter works. piece, was stay they’re mentioned. as how with why highly well. PAT we the that launch. need penetrated of in basically

those then are the And for it’s good I strokes. brush IPDE, So question. think major a

not the far, said, on as broadly. pleased a use the mention that Matt so as continue regimen. By always, don’t an I of calls, we’re as seen given should data that you of QINLOCK grow have We it’s we of IPDE. are lot for really we that right, said But prior of base this sort we way, promote So some. to off-label see data we

And do so we coverage bit a see inconsistent. some is currently payer

paid don’t. some claims get Some for

so this And it is at minimal rather time.

seeing consistent in So with it what you like are your pretty sounds survey.

Was there that impact price think before the follow-up I began. we increase, some you can If almost X% from that be model? about ask a on that, mean, quarter thinking we I guys as did should a take I

so price Steve. July Yes, X. take Chris, X.X% it’s did We increase as a of That’s right.

line with taken, increase oral oncolytics. other So we’ve with that what in that’s which we’ve price seen the is really

factors, were just Dan balance for of into thought play we of Dan of whole a quarter And to the variety contribute to as the them of spoke there different performance. year. just course, overall factors, price a wanted a there that, two, of that that we So that to outlined, including but variety highlight couple are

Okay, thanks.

And from Yang question thank from comes you. And Jefferies. our Eun next

Your line open. is now

Thank you.

fair of reduction in say for X seen opportunity dose that second question on in least, Matt, have allowing you certain So, to-date, we clinical would so be it’s in line you the and about the Xx to Phase based comments think INTRIGUE fourth greater line? second that are effect. do data Steve, toxic is on a guys based And trial, the at the your U.S., than event – GIST

revenue patients can planning may Tucker, certain at compare from Zai the to they second you are last to, planning are you. X revenues? royalty for what study had Thank collaboration you some Phase Pfizer’s So, group on is how the from and reduction point, to of to And in on question you Lab percent breakout comment dose certain line?

Hi, the for Eun, Steve. question. Thanks it’s

Matt way it question just second So opportunity your really to long And which second X,XXX two and the in line then opportunity the the take going Q&A, the U.S. really by of year. very in we in new are is the so think would think epidemiology, we are to patients on fourth of said see question relative line are treatment, about We patients One driven of And going patients line the about I is fourth let turn there before about, each about it’s Daniel INTRIGUE? second then I component about and me number that question. factors we that reiterate that to how eligible to we be have is what and is to to differences the are the to be Tucker, line from over the in those to those the drivers two that you Matt, biggest that the opportunity. therapy. treatment take the believe call earlier consistently. the staying duration relative really the first earlier talked about like

Matt. it’s Eun, Hi Sure.

in comparing study QINLOCK the second-line So our this Phase ripretinib X comparison. yes, to setting we have in sunitinib ongoing head-to-head

blinded on study modifications fully the enrolled to the or remain reductions treatment we know, patients per the We treatment but to not data, of other to the of as how last terms end have in study Simon, year. of the you arm. dose As of done only

indication which that – will in So, are planning to line the results, have fourth compared once the to sunitinib the quarter be this we have those labeled we this comparisons year, able indication of in the setting. make to we top

on breakout had we your Great. of components Tucker. quarters, as which commercial supply to question answer don’t now the have collaboration last collaboration clinical And we royalty initial or other well I revenues. moment, with the we QX, have then the it’s the as intention any payments. include various milestone in in will At revenue, the Eun, here Zai that payments. And

this quarter related does royalty a at the but other at payment, all both milestone components various broken the have the initial and to say collaboration, than So, haven’t it’s include supply but we where payments. commercial large to times out moment we Zai

you. Thank

from next you. Guggenheim comes thank Securities. And our from question Smith Michael And

is line Your now open.

commercial we the is This do where is question thus shift guess far of how line experience I launch trajectory your you the fourth have of how but one INTRIGUE presence have currently and Thanks. should before second fourth the accounts a number much at opportunity, first into potential for And think everybody. you I in the about Zhu guess on market line overlap afternoon present assuming patients given good line, sight to Michael. Hey, off I your the of in successful? Charles label. over pipeline, line commercial

Yes. would a Thanks, Charles. It’s great question. like that? take you Dan, to

for Yes, question. absolutely. Thanks the

that, leverage to to and treating pleased really targets fourth-line And ability with I’ve it’s one have remote when pandemic, ongoing So going the vast to pandemic, of launch the a we our in aren’t able because line been of those ways possible. did fourth majority virtual, also which have as the broadly launch of current but treaters, team challenges our a to finding in-person really is result target reach targets. know patient tough when. And interactions to but to and just have despite just great GIST treaters we a just reach drug prior been the really the hard job to both been – – it’s treaters of a we pivoting course,

treaters. in have patients they reached a to capitalize. that able We fourth of to we lines be identify are line, we so are of where So when quite also out do to earlier progress and work mindful number GIST do there

community. in GIST that get And – feel as are And there that So, a got larger the the as when excited then majority being we because about from the we long it are up think that’s are my for setting. to second-line sets prescribers now we really progress we line. remarks role we’ve we our is things market good the second new great even great an have. community have noted have of think like they play to in launch. out I we likely now the a made one prepared coming of I really feel mean, the we we for

second-line for expectations fourth has our have in foundation progress So, line and we and we with think pending line have right launch successful had in our got set great the been approval. the we a nice

maybe And how interest a that sense. that its literature of a is big autophagy, pathway. any are think, describes increased I on indicate that RAF-MEK-ERK alongside role one to front your Makes reliance looking out I I to of immune mechanism in particular, there clinical the And study? Matt, of in so how would a play Thanks. for autophagy guess, there at in an could characterize sort there addition lot valuable biomarkers autophagy can their guess, system? terms tumor on you immunization

you great please? It’s a Matt, Charles. question. ahead, don’t why go guys Hey,

Yes. Hi, Charles.

thanks both really autophagy of a and immune question. for the interesting, talking It’s role yes, surveillance. minute in the findings about in I can of So spend some the near

a I to in Well, some have in referred think study. who is you also that very published non-small patients it’s question of the very old that for we showing be And study followed cancer RAF lung by cell underway cancer will resistant subset recent combination are combination mutation. to LKB targeting Phase have exciting XXXX the XX% your a inhibitor data, comutation non-small PD-X, initial the mutant plus checkpoint our we pathway MAP now. are of with of kinase First, patients. progressing kinase This mutation by in so of initiation we of lung the and targeting PD-LX a RAS for with X cell single X RAS initially of our about combination agent cancer, blockade. occurs month excited They a study safety to about XXXX, the last announced first-in-human highly

kinase co-mutate greater PD-X have to than can as inhibitors less such for in cancer The being to and allow they XX% response they KV restore by this patients, if agents in that can in the responsiveness to So, showing response or rates mutation cells checkpoint cell comparison XX% of the pathway. that lung rate. or oral tumor it non-small X population, PD-LX provide carry immunoresponsiveness the well, inhibiting published that study as PD-X a

in So, that the for potential us opportunities terms combination in provides studies. of future

for the taking questions. Thanks it. Got

comes Securities. next And you. Robyn thank And from Truist our from Karnauskas question

now open. line is Your

you Robyn. for Kripa for much taking my on so Thank questions. is guys. Hey, This

expansion So, second both Hong opportunities I line Kong. talked and had about on EMA line and fourth launch eventually is China a question in just the still track in and your approval you in ex-U.S. about for quarter fourth

the to be how First, seems different preparedness can the countries? looking the EU, different to in especially on any COVID potential then will have regions you to about of you. either impact And approval, amongst given you on you situation talk us commercial beyond expansion it you Thank expect markets? easy other where strategy? there or approval where penetrate be where think Are and would meaningful be any color geographies

Yes. of Thanks, our about progress for Thanks U.S. Kripa. Steve. great question the It’s outside the

and posed. So, let me the that you address questions try

EU and First, Kong approval as in as that the see also have Greater four year. have you as territory, territory specifically. know, will now specifically we will of territory that and And Canada the online, we which Hong China territories in Australia. we we and to China approval expect all U.S., come Zai course, outside additional we, the additional in their the expect And approval this Zai that quarter of from of as noted, come you from our approval, and well in Zai both added the the approvals

And organization starting focus before markets. calls, on really progress address So, as of is, we in to the terms to in the early build our have on have access prior made really I Europe our opportunity good mentioned there.

So, markets, on freely as it and in others, have certain know, the price we on in may opportunity negotiation requires price reimbursement. a you to

end cases. result, right substantially But where can take getting in we potential making we longer Europe are to that done market talent, staged as year. on building very across approach the attracting Southern well to then also we will the opportunity team, relevant some a get we take work the access progress, the launch revenue. at the as both it build as good deliver only so, time, as for can not approval access as access, market this the EU we in but of will to And territories have And the as particularly be get very prepare and Europe, much a market in that so in the some in build

moving of So, we to there and the spent is addressed QINLOCK is geographic we with for time which about as basis you about. of second, a talked have really expansion as strategy respect key first, drug into two an expansion treatment. are the have lot for earlier strategy, previously areas the line That’s the INTRIGUE the of talking expansion. And study, about about

in really company, launch the So, to line and launch a is addition as second and where our is. the our course looking is U.S. fourth of about that focus line focus really for Europe to, here

that where access work markets. have go largest and distributors to already market those is Australia will we to ourselves to opportunity trying as are in we So through territories we try capture other in the in to Canada, demonstrated

being INVICTUS particular? patients to in the multiple differences you very I is you in you analysis of as of with question, that patients comparable background with, do Thank background seeing of to treated are it mutational mutational one If quarters, sure Are not more Great. ask a doing much much. how treated trial? QINLOCK. can you responders this are with Is a now, any couple more you have

Yes.

it’s of a on of size What unfortunately, question. INVICTUS sort expect we And So, those and who good the from setting. are enrolled don’t treated would data access where commercial based in we patients patients have really we good being of of about that background. to and is that the And very is study access we closely a is activity with earlier experience in where commercial treatment to. tracking we of drug irrespective persistency have saw the saw something mutational to broad Dan’s pretty the that duration I think consistent what INVICTUS INVICTUS, we comments

similar real to very to suggests world we the the INVICTUS population seeing setting treated what is behaving we drug are a us similarly. think patient in very and that I that that in

so much. Great. you Thank

And thank comes Reni you. next JMP Benjamin our from And Securities. question from

open. now is line Your

be that decision? carboplatinum. moving more to safety as to the given on we bit going little good we’re on that that taking as what data pretty afternoon will efficacy good the maybe to or we’ve a to led about efficacy sort And that for is, get you path patients or there X the move Was forward rebastinib questions. that, Thanks seen you likely as idea you what, you to we not going patients a Hey, guys. with seen at or get mentioned fair is more with I the forward what and just a updated side? sort program forward? have what you data than maybe through it are whether more you going know of about and to new here more to process you guess Can only program talk before, it it the side, the want same say is whatever have than safety X think decision-making – of it’s the ESMO before, we’re not

at month like PROC activity? the asked to Thanks, for and excited coming the the you Reni Matt, to to program. the about carbo question we are respect the profile of the drug as to cohort the Yes. versus relative noted, safety up address paclitaxel rebastinib And with would data question from here I share next Reni that ESMO.

Sure.

it’s So, Matt. hi, Reni,

inhibition macrophages So yes, as know, macrophages. TIEX so while potent And could the the the paclitaxel back, is in those And selected tumor as increase a just expressing promote angiogenesis TIEX as inhibitor you these kinase. endothelial models of block macrophages noticed on well TIEX back angiogenesis. number are androgenic that tumor cells we TIEX studies tumor preclinical as go expressed within rebastinib can did to and and We cell. well and as of

into trial. rebastinib, in X/X using and show we phase move the combination we’re Phase that carboplatinum that response. basis have this – could the the on We with that’s So forward a paclitaxel antitumor

while announced the see in into cohorts and carboplatinum the the patients to meet the not the enrollment for to objective response cohort activity safe, long to further we been we saw backbone in carboplatin but survival proceed time, looking not into addition, informative plan therapy there carboplatin. that have decided the next inform we’ve observation for forward level very on combination still In will very these present only in do updating progression-free a did they’ve combination I that as us cancer a extend the period rate, full month, of In now moving quite what at for it said evidence development, to was because these discontinued trial common But we earlier, planning clinical of and ESMO resistant expansion patients, indication. the at as regard in us today, is we of to patients we activity oncology, of also of trial. a be this ovarian with the we

of ahead to And when year, for as programs of the programs about the pivotal how of meet the we pivotal would buy-in think the end we of those the thinking the structure about programs regulatory starting? the finalization with should this of before that be at need timing as to you And the might FDA pivotal initiate?

Reni, it’s really good a question.

pieces right. and to exactly into evaluating data the in relevant I us performs a pivotal about, One, So, data moving the study. the presented you’re really information for as is the and we’ve are getting understanding consider two just talked and indication, drug of there how think

sure we we the about input pivotal think potential as have second make The good to is that for program. study a a regulatory of design

steps. the So those key be two would

position, a be to about we’ll forward looking as the getting data month. program there to like. half referenced start in look coming in up pivotal to could out So, the talk then next here noted what we’ve we’re second as And Matt a

you your drugs VPSXX, – switch you I the something that may control final you target own two works themselves development did combination molecules at blue Got or point – separately, that this talk guess there it. sort the might I is asset, overlap BD And biologically? VPSXX the question or the to pathways? And the have might of from was if with overlap for ULK be platform – then one biological about, of guess bit guys a a came try little what study, utilize find find to in that out can or how a new that inhibitor kinase

Reni. question, the for Thanks Yes.

just talk VPSXX first, program about first to we’re And today me I’ll autophagy referenced, X over excited patients. and program also and VPSXX in-class been potential which to bulk as not substantially done. how this interest internal two targeting it announce we’re which really of that but in, have our targeting have start But to if ways targets let VPSXX? cancer. excited was between But that we really might we’re pathway from otherwise so certainly would excited to for for now then this this and little we a pathway, tracking ULK, be And builds brought to have enrolling Matt, expertise to a have in underway differentiated. only stage the program licensing as turn advance the that versus our treatment me additional to they’re study upon So work Matt, talk And the have the the say you evaluating pursue, Phase you actively why that been we’ve we the don’t difference target targeting we’re Sprint. let off, of you research a a potential about targeting bit, targeting looking in that just would, the and

Steve, guys that. Hey, lose did you? I You didn’t hear

hearing you. having are we Matt, time hard Yes.

continue? Okay, can I

Yes.

so Reni, the ULK from question, its - for your start If I you the you can beginning VPSXX. and would beginning start from thank verses

hear – sorry. off, like it didn’t completely anything. Correct. And I I I’m cut Matt,

now, sorry. you Reni? Okay. No, me I’m Can hear

Yes, totally.

Yes. Okay.

back that And me leadership to inhibitors. VPSXX us add Steve of was Bioscience. let of saying, my in autophagy this as Sprint go build just recently a with excitement cancer about use from opportunity allow the with we So in-licensed the and will position treatment

that While VPSXX these within before for recycling involved the kinase node, we’ve regenerating different is works indicated vesicular autophagy, a energy. factor of trafficking the in is endosome at cargo old for initiating autophagosome

survival therapy. We in with for energy cells recently becomes tumor anti-cancer by and tumors And have work Institute that I Health distressed Luxembourg the with mechanism regenerating that treatment noting the was published of a the group of could killer also in to increases these to inflamed tumors the chemokines NK cells, Institute with immune inhibition and with tumors and with VPSXX T PD-X, cold checkpoint show sensitizing tumor inhibition blockers. that PD-LX along cells restore Karolinska

blockade. taken opportunity a provide together, have really checkpoint otherwise patients great can who are this not to that tumors for responsive So

very Thank taking it. the much for guys you, question. Got

question next Barclays. our And Peter you. comes Thank Lawson from from

is line now Your open.

Hi, taking question. thanks for the

Phase data how seeing in thoughts in of detail kind release the your and INTRIGUE on the the get on X Just just behaving. do we’re And the subgroup analysis? that level we just of could arm XQ, of control be

Peter, for it’s Steve. Thanks question. the

guidance in So probably study from I that from top terms to the what line INVICTUS presented the best is line, what out. top we we of about you previously as expect think when reported think the

however, some be a wouldn’t So line, have about investors line, top I study. will the analyses key readout information top take that deeper fulsome analysis it relatively of the and would likely providing imagine I a expect to to time. that subgroup

results. top best think the that’s to to way line I about what So from expect think

with and we’re itself, into great, of study forward the we’ve, report out. get looking the enrollment full year. has last really pleased conduct that fact course, line of been terms to study top to we’re The In the gotten

As studies. you know, blinded to the we’re

other don’t report may don’t blinded. additional insight accumulating, in have progressing the study out. because we we have arm. provide color as visibility to We But study any guidance on any able specifics into that how of by which on to aggregate, we arm I have the don’t course, things are So events know, we how said, is are how are given when we’re

just we ESMO. about then, And as think Okay.

forward in robust to that? move So you ovarian, for what’s the bar with

Yes.

that as patient mentioned would population prepared amplify agent on of So like. progression-free months. Matt X Matt, survival remarks and somewhere free I of think in – feel in order We a you’d paclitaxel will expect deliver his the that, X if to this single to

to specific need we different agent something paclitaxel. I So that’s see what would substantially would we bar, Peter, is what expect think to from with guided a single see to haven’t but we

that expect we you. Perfect. just on should at at data? detail efficacy level final just question, the kind ESMO what see And Thank to initial TGCT around of of then

– what I in you would prepared detail provide you Matt, you on like think, this know some to I Sure. some remarks. in covered expect your there? of additional

Sure. the No, Peter, question. thanks. for thanks, And

very we’ve the noted, rapid is into the inhibitor in receptor Phase So of and treating the selective potent as patients we now and development had X/X enrollment with study. CSFX And Vimseltinib our for TGCT.

expansion designed as patients, So a the first previously-treated with second was X just into one phase the treatment-naive cohorts, both reminder, in an – study escalation cohort expansion patients. and

and the note, a be with at XX meeting now treatment-naive report enrolled year. on escalation both the double expansion patients able the patient TGCT patients more that is well on cohort XX ASCO’s XX phases the fully And we next just CTOS we So report we’ll as cohort patients, fully were month. with expansion data the approximately XX this ESMO patients as at to than to able enrolling patients XX as and last from

Perfect. Thank much. you so

Canaccord. you. Lee our from Arlinda Thank next from question And comes

open. Your line is now

line. so And patients experienced. XX the ESMO, Great. bit Thanks maybe the the sorry, going to a and you questions. INTRIGUE second taking a both are on include for my then, I on – at CSFX-naive clarify you little can can couple, had Vimseltinib

exon aggregate about expectations, the I the for are efficacy, assumptions X.X your wondering with are? have being maybe point. patients of – information in Thank maybe talk think You to have you. and just at this Can you month assumptions I’m think mentioned XX/XX you mutation, do that you what X what you proportion then sutent what your

Steve. it’s Arlinda,

question, the your I’ll let question. Matt take to So part the me sunitinib just and of then ask second address

with respect are to study. blinded to first, we INTRIGUE, the So

things are patients such enrolled study. that to visibility the have don’t being as we of the in status mutation So profile or

by something what to have And how second-line in we’ve study ripretinib visibility where about to. PFS our rate respect Phase we the really Now with that X in we cohort patients. seen that with may saw perform of impressive is an in the driven study the isn’t ripretinib assumptions

months. about from of to the you we for anchor, which course, in same X.X expect study, label terms that In in of was what sutent sutent, what’s

– sutent terms that range we’ve X expect So we the PFS. in in month of would perform

efficacy from coming Matt, So would ESMO? Vimseltinib that’s part with potentially to take the respect the like the how INTRIGUE. we think about to you story question of

Sure.

it to – a that’s So study, to treating-naive to go limit inhibitor we treatment-naive phase report just not patients. patients back both efficacy. on the able cohort a it that or was so for mix with escalation of be our of to patients, the pre-treated did treatment And the we’ll CSFX XX-patient

and efficacy set patients. treatment will the treatment-naive of also ESMO. still a XX patients, is data an from we’ll enrolled that safest of we at that, be on that have – cohort and group part the enrollment to addition we’ll that valuable time patients at In enrolling, cohort previously present but update treated of The

great. much. you Thank Okay, very

remarks. for you question. Steve back call showing to thank President that And now for turn like over no Hoerter, the and to further I questions. I’m closing would CEO,

you. great for of Thanks, XXXX. balance you you Thank support keeping continuing Thank us you. joining for everybody, today’s Hope for Great. evening. a updated all interest on to your have you progress call, on forward and continued and our thank We the of Deciphera. look

today’s This you concludes conference for participating. call. Thank

disconnect. now may You